Cargando…
Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study
BACKGROUND: Preventing intracranial hematoma expansion has been advertised as a possible treatment opportunity in traumatic brain injury (TBI). However, the time course of hematoma expansion, and whether the expansion affects outcome, remains poorly understood. In light of this, the aim of this stud...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935722/ https://www.ncbi.nlm.nih.gov/pubmed/36167951 http://dx.doi.org/10.1007/s12028-022-01609-w |
_version_ | 1784890079469109248 |
---|---|
author | Fletcher-Sandersjöö, Alexander Tatter, Charles Tjerkaski, Jonathan Bartek, Jiri Maegele, Marc Nelson, David W. Svensson, Mikael Thelin, Eric Peter Bellander, Bo-Michael |
author_facet | Fletcher-Sandersjöö, Alexander Tatter, Charles Tjerkaski, Jonathan Bartek, Jiri Maegele, Marc Nelson, David W. Svensson, Mikael Thelin, Eric Peter Bellander, Bo-Michael |
author_sort | Fletcher-Sandersjöö, Alexander |
collection | PubMed |
description | BACKGROUND: Preventing intracranial hematoma expansion has been advertised as a possible treatment opportunity in traumatic brain injury (TBI). However, the time course of hematoma expansion, and whether the expansion affects outcome, remains poorly understood. In light of this, the aim of this study was to use 3D volume rendering to determine how traumatic intracranial hematomas expand over time and evaluate its impact on outcome. METHODS: Single-center, population-based, observational cohort study of adults with moderate-to-severe TBI. Hematoma expansion was defined as the change in hematoma volume from the baseline computed tomography scan until the lesion had stopped progressing. Volumes were calculated by using semiautomated volumetric segmentation. Functional outcome was measured by using the 12 month Glasgow outcome scale (GOS). RESULTS: In total, 643 patients were included. The mean baseline hematoma volume was 4.2 ml, and the subsequent mean hematoma expansion was 3.8 ml. Overall, 33% of hematomas had stopped progressing within 3 h, and 94% of hematomas had stopped progressing within 24 h of injury. Contusions expanded significantly more, and for a longer period of time, than extra-axial hematomas. There was a significant dose–response relationship between hematoma expansion and 12 month GOS, even after adjusting for known outcome predictors, with every 1-ml increase in hematoma volume associated with a 6% increased risk of 1-point GOS deduction. CONCLUSIONS: Hematoma expansion is a driver of unfavorable outcome in TBI, with small changes in hematoma volume also impacting functional outcome. This study also proposes a wider window of opportunity to prevent lesion progression than what has previously been suggested. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12028-022-01609-w. |
format | Online Article Text |
id | pubmed-9935722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-99357222023-02-18 Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study Fletcher-Sandersjöö, Alexander Tatter, Charles Tjerkaski, Jonathan Bartek, Jiri Maegele, Marc Nelson, David W. Svensson, Mikael Thelin, Eric Peter Bellander, Bo-Michael Neurocrit Care Original Work BACKGROUND: Preventing intracranial hematoma expansion has been advertised as a possible treatment opportunity in traumatic brain injury (TBI). However, the time course of hematoma expansion, and whether the expansion affects outcome, remains poorly understood. In light of this, the aim of this study was to use 3D volume rendering to determine how traumatic intracranial hematomas expand over time and evaluate its impact on outcome. METHODS: Single-center, population-based, observational cohort study of adults with moderate-to-severe TBI. Hematoma expansion was defined as the change in hematoma volume from the baseline computed tomography scan until the lesion had stopped progressing. Volumes were calculated by using semiautomated volumetric segmentation. Functional outcome was measured by using the 12 month Glasgow outcome scale (GOS). RESULTS: In total, 643 patients were included. The mean baseline hematoma volume was 4.2 ml, and the subsequent mean hematoma expansion was 3.8 ml. Overall, 33% of hematomas had stopped progressing within 3 h, and 94% of hematomas had stopped progressing within 24 h of injury. Contusions expanded significantly more, and for a longer period of time, than extra-axial hematomas. There was a significant dose–response relationship between hematoma expansion and 12 month GOS, even after adjusting for known outcome predictors, with every 1-ml increase in hematoma volume associated with a 6% increased risk of 1-point GOS deduction. CONCLUSIONS: Hematoma expansion is a driver of unfavorable outcome in TBI, with small changes in hematoma volume also impacting functional outcome. This study also proposes a wider window of opportunity to prevent lesion progression than what has previously been suggested. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12028-022-01609-w. Springer US 2022-09-27 2023 /pmc/articles/PMC9935722/ /pubmed/36167951 http://dx.doi.org/10.1007/s12028-022-01609-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Work Fletcher-Sandersjöö, Alexander Tatter, Charles Tjerkaski, Jonathan Bartek, Jiri Maegele, Marc Nelson, David W. Svensson, Mikael Thelin, Eric Peter Bellander, Bo-Michael Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title | Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title_full | Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title_fullStr | Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title_full_unstemmed | Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title_short | Time Course and Clinical Significance of Hematoma Expansion in Moderate-to-Severe Traumatic Brain Injury: An Observational Cohort Study |
title_sort | time course and clinical significance of hematoma expansion in moderate-to-severe traumatic brain injury: an observational cohort study |
topic | Original Work |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935722/ https://www.ncbi.nlm.nih.gov/pubmed/36167951 http://dx.doi.org/10.1007/s12028-022-01609-w |
work_keys_str_mv | AT fletchersandersjooalexander timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT tattercharles timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT tjerkaskijonathan timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT bartekjiri timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT maegelemarc timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT nelsondavidw timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT svenssonmikael timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT thelinericpeter timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy AT bellanderbomichael timecourseandclinicalsignificanceofhematomaexpansioninmoderatetoseveretraumaticbraininjuryanobservationalcohortstudy |